Enlivex Therapeutics Reports Positive Phase II Trial Data
Ticker: ENLV · Form: 6-K · Filed: Mar 3, 2025 · CIK: 1596812
Sentiment: bullish
Topics: clinical-trial, drug-development, press-release
TL;DR
Enlivex's Phase II trial shows positive interim results for Allocetra™.
AI Summary
On March 3, 2025, Enlivex Therapeutics Ltd. announced positive interim six-month efficacy data from the first stage of its Phase II Allocetra™ trial. The trial is a randomized, multi-country study evaluating the drug's effectiveness.
Why It Matters
Positive trial results could advance Enlivex's drug candidate, potentially impacting future treatment options and the company's market position.
Risk Assessment
Risk Level: medium — Phase II trial data is promising but requires further validation in later stages, and regulatory approval is not guaranteed.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- Allocetra™ (drug) — Investigational drug
- March 3, 2025 (date) — Date of press release
- Phase II (trial_stage) — Clinical trial phase
FAQ
What specific positive efficacy data was announced for the Allocetra™ trial?
The filing states positive interim six-month efficacy data was announced, but does not provide specific quantitative details in this excerpt.
What is the name of the drug being tested?
The drug being tested is named Allocetra™.
What is the current stage of the clinical trial for Allocetra™?
The current stage of the clinical trial is Phase II.
When was the press release announcing the trial data filed?
The press release was issued on March 3, 2025.
In which country is Enlivex Therapeutics Ltd. incorporated?
Enlivex Therapeutics Ltd. is a company organized under the laws of the State of Israel.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 3, 2025 regarding Enlivex Therapeutics Ltd. (ENLV).